Pharmaceuticals (Basel, Switzerland)
Tumor Characterization Using [18F]FDG PET Radiomics in a PD-L1-Positive NSCLC Cohort.
Bernadett Erzsébet Kálmán, Agnieszka Bos-Liedke, Dániel Dezső, Ewelina Kaminska, Mateusz Matusewicz, Ferenc Budán, Domokos Mathe, János Girán, Dávid Sipos, Éva Pusztai, Árpád Boronkai, Zsombor Ritter
Published: 202610.3390/ph19010103
Abstract
Background: Durvalumab consolidation following radiochemotherapy is now the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). [18F]FDG PET/CT offers valuable insights not just for staging but also for tumor characteriz…
Preview only. Read the full abstract at the source